Practical aspects of the oral new anticoagulants

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Thrombosis Research

Background:

• Oral vitamin K antagonists have long been the standard for antithrombotic therapy.
• A new generation of oral anticoagulants is emerging, offering different mechanisms of action and potentially improved safety profiles.
• These novel agents include direct thrombin inhibitors and factor Xa inhibitors.

Purpose of the Study:

• To review clinical trial data for novel oral antithrombotic agents, focusing on dabigatran, rivaroxaban, and apixaban.
• To discuss practical considerations for the clinical use of these new agents.
• To provide an overview of monitoring, reversal strategies, and management before procedures.

Main Methods:

• Systematic review of published clinical trial results.
• Analysis of data regarding efficacy and safety endpoints.
• Discussion of practical aspects based on current literature and guidelines.

Main Results:

• Dabigatran, rivaroxaban, and apixaban have demonstrated non-inferiority or superiority to vitamin K antagonists in major bleeding and thrombotic events across various trials.
• Each agent has a distinct pharmacokinetic and pharmacodynamic profile influencing their use.
• Reversal agents and specific monitoring techniques are becoming increasingly important for safe management.

Conclusions:

• Novel oral antithrombotic agents represent a significant advancement in anticoagulation therapy.
• Careful patient selection, understanding of individual agent characteristics, and preparedness for management scenarios are crucial for optimal outcomes.
• These agents are poised to become integral components of antithrombotic treatment strategies.